MatthewMHeeneyMD(He/Him)
Pediatric Hematology & Oncology • Boston, MAAssociate Professor of Pediatrics, Harvard Medical School
Dr. Heeney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-919-3242Fax+1 617-730-0641
Summary
- Dr. Matthew Heeney is a pediatric hematologist/oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and Boston Medical Center. He received his medical degree from University of Calgary Faculty of Medicine and has been in practice 22 years. He also speaks multiple languages, including French. He is experienced in hemochromatosis, iron deficiency anemia, pediatric hematology / oncology, sideroblastic anemia, and pediatric sickle cell anemia.
Education & Training
Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1999 - 2002
McGill University Faculty Medicine HospitalPediatrics, 1995 - 1999
University of Calgary Faculty of MedicineClass of 1995
Certifications & Licensure
MA State Medical License 2002 - 2025
VA State Medical License 2002 - 2004
NC State Medical License 1999 - 2002- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis Start of enrollment: 2005 Apr 01
- Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Start of enrollment: 2005 Aug 01
- Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 191 citationsPost-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell DiseaseErica B. Esrick, Leslie Lehmann, Alessandra Biffi, Maureen Achebe, Christian Brendel
The New England Journal of Medicine. 2021-01-21 - 272 citationsDefinitions of the phenotypic manifestations of sickle cell diseaseSamir K. Ballas, Susan Lieff, Lennette Benjamin, Carlton Dampier, Matthew M. Heeney
American Journal of Hematology. 2009-09-24 - 130 citationsMutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)Pranesh Chakraborty, Klaus Schmitz-Abe, Erin K. Kennedy, Hapsatou Mamady, Turaya Naas
Blood. 2014-10-30
Journal Articles
- The Phenotypic Spectrum of Germline YARS2 Variants: From Isolated Sideroblastic Anemia to Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia 2Matthew M Heeney, Gregory A Hale, David P Steensma, Mark D Fleming, Colin A Sieff, Lee M Hilliard, Sylvia S Bottomley, Janet L Kwiatkowski, Haematologica
Press Mentions
- VIDEO: Dosing Evaluation Trial Aims to ‘Broaden the Label’ for Sickle Cell TreatmentDecember 20th, 2021
Treating Sickle Cell Disease with HSCTFebruary 19th, 2020- Sickle Cell Disease and Quality of Life ConcernsJanuary 31st, 2020
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
